Document:

<PAGE>

Exhibit 10.1                                                    Thomas B. Clark

                                   AGREEMENT
                            TO FOREGO COMPENSATION

An Agreement is made between Thomas B. Clark (the "Executive") and Alltrista
Corporation (the "Company").

WHEREAS, the Executive has been and continues to be a valued key executive of
the Company;

WHEREAS, the Company desires to make a loan to the Executive; and

WHEREAS, the Executive agrees to forego all of the balances payable to the
Executive under the 1993 Deferred Compensation Plan and the Excess Savings and
Retirement Plan (the "Plans").

NOW, THEREFORE, in consideration for the aforementioned promises, and for other
consideration, the receipt and sufficiency of which is hereby acknowledged, the
parties agree as follows, intending to be legally bound.

1.   The Company agrees to enter into a loan agreement (the "Loan Agreement") to
     provide a loan to the Executive.  The terms of the loan shall be documented
     by a Promissory Note (the "Note") to be executed by the Company and the
     Executive.

2.   In consideration for the Company's promise to enter into the Loan
     Agreement, the Executive's account balances in the Plans shall be reduced
     to zero effective March 31, 2001.  The Executive's balances in the Plans
     shall be foregone by the Executive, and the Executive hereby irrevocably
     waives his right to payment of such amount.

3.   The Executive agrees that:  the Company has not advised him as to any
     financial or tax risks associated with this Agreement or the Loan Agreement
     and Note to be entered into pursuant to this Agreement; that the Executive
     has relied solely on his personal advisors in deciding to enter into this
     Agreement and the related transactions; and, that the Executive (and his
     successors, heirs and assigns) assume responsibility for any tax or
     financial risks incurred by the Executive (or his successors, heirs and
     assigns) resulting from the transaction.

IN WITNESS WHEREOF, the parties hereby execute this Agreement, intending to be
legally bound,

                                                   Alltrista Corporation

/s/ Thomas B. Clark                                By: /s/ Kevin D. Bower
-----------------------------------                -----------------------------
Thomas B. Clark

March 27, 2001                                     March 27, 2001
-----------------------------------                -----------------------------
Date                                               Date<PAGE>

Exhibit 10.2                                                      Kevin D. Bower

                                   AGREEMENT
                            TO FOREGO COMPENSATION

An Agreement is made between Kevin D. Bower (the "Executive") and Alltrista
Corporation (the "Company").

WHEREAS, the Executive has been and continues to be a valued key executive of
the Company;

WHEREAS, the Company desires to make a loan to the Executive; and

WHEREAS, the Executive agrees to forego all of the balances payable to the
Executive under the 1993 Deferred Compensation Plan and the Excess Savings and
Retirement Plan (the "Plans").

NOW, THEREFORE, in consideration for the aforementioned promises, and for other
consideration, the receipt and sufficiency of which is hereby acknowledged, the
parties agree as follows, intending to be legally bound.

1.   The Company agrees to enter into a loan agreement (the "Loan Agreement") to
     provide a loan to the Executive.  The terms of the loan shall be documented
     by a Promissory Note (the "Note") to be executed by the Company and the
     Executive.

2.   In consideration for the Company's promise to enter into the Loan
     Agreement, the Executive's account balances in the Plans shall be reduced
     to zero effective March 31, 2001.  The Executive's balances in the Plans
     shall be foregone by the Executive, and the Executive hereby irrevocably
     waives his right to payment of such amount.

3.   The Executive agrees that:  the Company has not advised him as to any
     financial or tax risks associated with this Agreement or the Loan Agreement
     and Note to be entered into pursuant to this Agreement; that the Executive
     has relied solely on his personal advisors in deciding to enter into this
     Agreement and the related transactions; and, that the Executive (and his
     successors, heirs and assigns) assume responsibility for any tax or
     financial risks incurred by the Executive (or his successors, heirs and
     assigns) resulting from the transaction.

IN WITNESS WHEREOF, the parties hereby execute this Agreement, intending to be
legally bound,

                                                   Alltrista Corporation

/s/ Kevin D. Bower                                 By: /s/ Thomas B. Clark
-----------------------------                      -----------------------------
Kevin D. Bower

March 29, 2001                                     March 29, 2001
-----------------------------                      -----------------------------
Date                                               Date<PAGE>

                                                      CONFIDENTIAL TREATMENT
                                                      ----------------------

                                                                   Exhibit 10.23

February 28, 2001

Mr. Stephen Winjum
NovaMed Eyecare Services, L.L.C.
980 North Michigan Avenue
Suite 1620
Chicago, Illinois 60611

Re:  LADARVision(R) Agreement
     ------------------------

Dear Steve:

This letter, when countersigned by you on behalf of NovaMed Eyecare Services,
LLC ("NovaMed"), will constitute a binding agreement between NovaMed and Alcon
Laboratories, Inc. ("ALI") and RefractiveHorizons, L.P. ("RH") wherein NovaMed
will obtain ALI's LADARVision(R) Systems on the terms and conditions set forth
below (the "Agreement"). The effective date of this agreement will be March 1,
2001 ("Effective Date").

Our agreement is as follows:

1.   Existing Agreements. NovaMed understands and acknowledges that during the
     year 2000, ALI acquired Summit Autonomous, Inc., formerly consisting of
     Summit Technology, Inc. and Autonomous Technologies Corporation. All
     previous agreements entered between NovaMed, Summit Technology, Inc.,
     and/or Autonomous Technologies Corporation, including, but not limited to,
     the NovaMed-Summit Agreement entitled "An Opportunity for Rapid Expansion
     into the Business of Laser Vision Correction" dated as of October 2, 1998,
     as amended by (i) a First Amendment dated April 2, 1999, (ii) a Second
     Amendment dated May 21, 1999, (iii) an Amended and Restated NovaMed/Summit
     Agreement dated as of July 7, 1999, (iv) a First Amendment to the Amended
     and Restated NovaMed/Summit Agreement dated as of October 1, 1999, (v) a
     Second Amendment to the Amended and Restated NovaMed/Summit Agreement dated
     as of November 1, 1999, (vi) a Third Amendment to the NovaMed-Summit
     Agreement dated February 23, 2000; and (vii) all Omnicard Plus Agreements
     executed in connection with any APEX/Infinity laser covered by the
     foregoing (collectively, the "Original Agreement"), shall be terminated as
     of the Effective Date. Notwithstanding the foregoing, all amounts owed by
     either party pursuant to the Original Agreement which relate to Procedures
     performed prior to March 1, 2001 will be paid. In terminating the Original
     Agreement, and subject to Sections 4 and 16 of this Agreement, the parties
     hereto agree that * . In this regard, and without limiting the terms of
     this Section 1, NovaMed will * . NovaMed will only purchase Omnicards on *
     as set forth in Section 1 (h) below and at the price set forth in Section 4
     hereof. The following terms will apply with respect to all APEX/Infinity
     lasers currently used by

*Confidentiality portions omitted and filed separately with the Commission.
<PAGE>

Mr. Stephen Winjum                                        CONFIDENTIAL TREATMENT
February 28, 2001                                         ----------------------
Page 2

NovaMed Parties (defined in Section 3 below) for so long as such
APEX/Infinity lasers are in use:

a.   ALI agrees to continuously maintain the APEX/Infinity lasers per the Gold
     Standard Service Agreement attached hereto as Exhibit A, at * to NovaMed
     for all current APEX/Infinity lasers until December 31, 2003. Beginning
     January 1, 2004, this maintenance will continue at * for up to *
     APEX/Infinity lasers for as long as the APEX/Infinity lasers are in use.
     For any APEX/Infinity lasers in excess of * , maintenance will be charged
     at the rate of * per APEX/Infinity laser.

b.   ALI agrees to continuously maintain the software on the APEX/Infinity
     lasers at * such that the software is always consistent with the highest
     level of software relevant and legally available for the APEX/Infinity
     laser, including, without limitation, P-disks, once approved.

c.   The Omnicard fee described in Section 4 hereof covers out-of-pocket
     costs to be paid by NovaMed to ALI in connection with the
     APEX/Infinity lasers, including, without limitation, maintenance, ArF
     gas, Omnicards, emphasis discs, and technical and clinical support,
     except that NovaMed will be responsible for nitrogen and helium gas.

d.   The Omnicard fees will be a per procedure, or per eye, fee * .

e.   Prior to December 31, 2003, during each calendar quarter during the Term,
     NovaMed will * for bona fide retreatments performed on any APEX/Infinity
     laser (provided the original procedure was performed on an APEX/Infinity
     laser) until the number of retreatments exceeds * . Beginning January 1,
     2004 and continuing through December 31, 2004, during each calendar quarter
     during the Term, NovaMed will * for bona fide retreatments performed on any
     APEX/Infinity laser (provided the original procedure was performed on an
     APEX/Infinity laser) until the number of retreatments exceeds * .
     Thereafter, all retreatments on the APEX/Infinity lasers will be billed at
     * per procedure. *      .

f.   RH represents and warrants that it has assumed the Summit Laser Patent
     Licenses relating to the existing APEX/Infinity lasers. Such licenses will
     remain in full force and effect, subject to the pricing for Omnicards as
     stated in this Agreement.

g.   ALI hereby indemnifies NovaMed for any failure on the part of Summit
     Technology, Inc. to remit historical lease payments to Health Capital
     as required pursuant to the terms and conditions of the Original
     Agreement.

h.   NovaMed has an existing inventory of Omnicards for use on the APEX/Infinity
     lasers. NovaMed further agrees to provide ALI with an inventory of
     Omnicards for each APEX/Infinity laser on a quarterly basis within thirty
     (30) days following

*Confidentiality portions omitted and filed separately with the Commission.

<PAGE>

Mr. Stephen Winjum                                        CONFIDENTIAL TREATMENT
February 28, 2001                                         ----------------------
Page 3

     the end of each quarter. The parties hereto agree that those Omnicards may
     be used on any and all APEX/Infinity laser covered under the Original
     Agreement, and will not be limited to a particular laser.

2.   Term. The term of this Agreement is five (5) years following the Effective
     Date (the "Term"). For any System in place at a NovaMed Party (as defined
     in section 3 below) at the end of the five-year Term referenced above, (a)
     NovaMed will cease using such Systems at the end of the Term and will
     return all such Systems to ALI within thirty (30) days following the end of
     the Term, or (b) ALI will remove such Systems at the end of the Term, or
     (c) the Systems will remain in place and the parties will negotiate in good
     faith new agreements for the provision of per procedure fees, service,
     parts, optics and the like.

3.   Laser Placements. During the Term, NovaMed will have the right to obtain
     from ALI an unlimited number of ALI's LADARVision(R) Systems (hereinafter
     collectively referred to as the "Systems" and individually as a "System")
     pursuant to the terms of this Agreement. ALI agrees to deliver and install
     such Systems within a reasonable period following NovaMed's request for
     such Systems. NovaMed further agrees to order * Systems on the Effective
     Date and agrees to take delivery and installation of * such Systems by
     March 31, 2001 and of the * remaining Systems by April 15, 2001 (excluding
     the HEC LADARVision System in Section 13 and the Dr. Tim Schmitt System in
     Section 14). Systems may be procured hereunder by or on behalf of any of
     the following ("NovaMed Party or Parties"): (i) NovaMed; (ii) NovaMed
     Eyecare, Inc. ("Nova"), the parent company of NovaMed, and any subsidiary
     of Nova (such subsidiaries, together with Nova and NovaMed, shall be
     individually referred to as a "NovaMed Entity" and collectively as the
     "NovaMed Entities") * .

     As used herein, "NovaMed Services" shall mean information technology-based
     services and/or other services designed to assist health care providers in
     the growth and development of their business, which services may include,
     without limitation, any of the following: installation, maintenance,
     hosting and support of information technology systems; installation,
     maintenance and support of lasers and other equipment used to perform
     vision correction or other surgical procedures; sales and marketing
     products and services; financial and operations management services;
     management or other services relating to the operation of an ambulatory
     surgery center, vision correction center or other surgical facility;
     patient financing and credit card services; and other electronic services
     and related electronic commerce capabilities.

4.   Omnicards. Commencing on the Effective Date and continuing thereafter for
     so long as the existing APEX/Infinity lasers are being used by NovaMed
     Parties (as defined in Section 3 above), NovaMed may purchase Omnicards
     used to operate such APEX/Infinity lasers at a price equal to the
     following: (i) * per Omnicard purchased prior to July 1, 2002; and (ii) *
     Omnicard purchased after June 30, 2002. Commencing on July 1, 2002 and
     continuing thereafter during the Term, the per Procedure fee for the
     APEX/Infinity lasers will be determined per Sections 6-8 below * .
     Moreover,

*Confidentiality portions omitted and filed separately with the Commission.
<PAGE>

Mr. Stephen Winjum                                        CONFIDENTIAL TREATMENT
February 28, 2001                                         ----------------------
Page 4

     NovaMed agrees to sell to ALI and ALI agrees to repurchase from NovaMed,
     all existing inventory of Omnicards as of June 30, 2002 for * per Omnicard.

5.   *

6.   Procedure Pricing. During the Term, NovaMed will pay a combined per
     Procedure fee to ALI and RH of * ( * of Procedure fee paid to ALI pursuant
     to the terms and conditions of LADARVision Placement Contract attached
     hereto as Exhibit C, and * of Procedure fee paid to RH pursuant to Laser
     Patent Software License Agreement attached hereto as Exhibit D) for each
     Procedure performed on a System obtained pursuant to this Agreement * . In
     the event of a conflict between this Agreement and any of the Exhibits
     attached hereto, the terms and conditions of this Agreement shall control.

     In lieu of NovaMed paying the aggregate per Procedure fees * on a quarterly
     basis, the per Procedure fees will be payable by NovaMed to ALI and RH on a
     monthly basis, with payment due net 30 days, as follows: during the first
     three months of each calendar quarter, the per Procedure fee for Procedures
     performed on Systems during such three months will equal the average per
     Procedure fee * payable by NovaMed to ALI and RH for Procedures performed
     during the preceding calendar quarter. All amounts due, but not paid on the
     due date, will accrue interest at the rate of 1.5% per month or such other
     maximum rate allowed by law, whichever is less. The foregoing terms are
     payment terms only, and the ultimate per Procedure fees due and owing will
     be reconciled per Sections 6-8 and Section 12 hereof.

     As used herein, the term "Procedure" means any ophthalmic procedure, per
     eye, performed on a System or any procedures performed on an APEX/Infinity
     laser after March 1, 2001, the purpose or effect of which is to alter
     refraction of the human eye, but does not include bona fide retreatments
     (hereafter referred to as "Retreatments"). Further, the term "Procedure"
     does not and will not include Custom Cornea(R) equipment, software and
     procedures if, as and when approved. Retreatment procedures performed on
     the Systems will be priced at * per Procedure. Retreatments include any
     Retreatments performed on patients who were originally treated on any laser
     owned by NovaMed (including any APEX/Infinity lasers covered hereunder)
     where the initial procedure was performed within eighteen (18) months of
     the date of the Retreatment.

7.   Minimum Procedures. NovaMed agrees to an annual minimum commitment volume
     of * Procedures per System, based on the average number of Procedures for
     all Systems obtained by NovaMed pursuant to this Agreement. Should the
     average number of Procedures per System for all of the Systems fall
     below * Procedures for a particular year, RH and ALI shall bill NovaMed for
     the shortfall at a combined rate of * per Procedure. The average number of
     Procedures per System will be computed pursuant to Section 12 below on a
     calendar year basis, with estimated short fall billings, if any, billed on
     a quarterly basis, and adjusted to actual at year end. Any short fall
     payment will be

*Confidentiality portions omitted and filed separately with the Commission.
<PAGE>

Mr. Stephen Winjum                                        CONFIDENTIAL TREATMENT
February 28, 2001                                         ----------------------
Page 5

     due net 30 days. Late payments to accrue interest at the rate of 1.5% per
     month or such other maximum rate as allowed by law, whichever is less.

8.   *

9.   Microkeratome Placements. For each System obtained by NovaMed pursuant to
     this Agreement, ALI will supply NovaMed, * with one Summit Krumeich-
     Barraquer Microkeratome ("SKBM") and will include one head and one set of
     rings (hereinafter referred to as the "Standard Configuration").

10.  Blade Pricing. For each SKBM obtained pursuant to this Agreement, NovaMed
     will pay a price of * for each SKBM blade * .

11.  *

12.  Calculation of Average Number of Procedures. For purposes of calculating
     the average annual Procedures per System for sections 7 and 8, the
     following methodology will be used. Calculations will be made on a calendar
     year basis ending December 31 of each year (including 2001). *

     * , the average number of Procedures per System is equal to the sum of
     total Procedures performed during the calendar year divided by the sum of
     the cumulative Systems in service for each full month of the year times 12.

     For purposes of calculating the annual minimum commitment volume of *
     Procedures per System under Section 7, the average number of Procedures per
     System will be equal to the total Procedures performed during the calendar
     year on all Systems obtained pursuant to this Agreement and including
     Systems (and the Procedures performed thereon) obtained pursuant to
     Sections 13 and 14 hereof, divided by the sum of the cumulative Systems in
     service for each full month of the year times 12.

     *

     *

     Procedures performed prior to the Effective Date on the Systems described
     in Section 14 shall be added to the number of Procedures performed on such
     Systems during the month of March 2001 for the purposes of making the
     calculations under this Section 12.

     A System will be included in the cumulative Systems number beginning in the
     first full month after installation. See below for an example of such a
     calculation where a total of 20 Systems are in operation at year-end.

*Confidentiality portions omitted and filed separately with the Commission.
<PAGE>

Mr. Stephen Winjum                                        CONFIDENTIAL TREATMENT
February 28, 2001                                         ----------------------
Page 6

<TABLE>
<CAPTION>

                                                 Total
                                               Procedures        Total
                                              Performed on     Procedures
                                Total           Section       Performed on
             Cumulative         System         13 and 14      APEX/Infinity
Month        Systems (a)    Procedures (b)      Systems        Lasers (c)
<S>          <C>            <C>               <C>             <C>

January           *                *               *                *
February          *                *               *                *
March             *                *               *                *
April             *                *               *                *
May               *                *               *                *
June              *                *               *                *
July              *                *               *                *
August            *                *               *                *
September         *                *               *                *
October           *                *               *                *
November          *                *               *                *
December          *                *               *                *
                  -                -               -                -
Total             *                *               *                *
                  -                -               -                -
</TABLE>

(a)  Cumulative Systems installed pursuant to this Agreement.  A System will be
     included in the cumulative Systems numbers beginning in the first full
     month after installation.  Cumulative Systems are Systems only and do not
     include any APEX/Infinity lasers.

(b)  Total Procedures, which exclude Retreatments, performed on Systems during a
     given month.  Includes Procedures performed on the HEC (Section 13) and
     Section 14 Systems.  Also includes Procedures performed on  Systems prior
     to the first full month after installation.

(c)  Total Procedures, which excludes Retreatments, performed on APEX/Infinity
     lasers.

<TABLE>
<CAPTION>
<S>                                               <C>
Annual Minimum Commitment Calculation:
  Average Procedures per month                    *
  Average annual number of Procedures per
   System for all Systems under this Agreement    *

*

  Average Procedures per month                    *
  Average annual number of Procedures per
   System for all Systems under this agreement    *
</TABLE>

*Confidentiality portions omitted and filed separately with the Commission.

<PAGE>

Mr. Stephen Winjum                                        CONFIDENTIAL TREATMENT
February 28, 2001                                         ----------------------
Page 7

     Therefore, NovaMed has achieved an annual performance average of *
     Procedures per System  *

          *
            Average Procedures per month                      *
            Average annual number of Procedures per
              System for all Systems under this Agreement     *

     *

     * This  *  is used to bill Procedures during the next quarter
     consistent with Section 6 of this Agreement.  At the end of each year,
     NovaMed is required to have paid ALI and RH for total Procedures  *
     calculated on a calendar year basis consistent with the terms of this
     Agreement.

13.  HEC LADARVision(R) System. The parties acknowledge and agree that one
     System has been placed at the Hunkeler Eye Centers (the "HEC LADARVision(R)
     System") prior to the Effective Date of this Agreement. The pricing for the
     HEC LADARVision(R) System will be * per Procedure through June 30, 2002.
     The pricing for the Procedures performed prior to March 1, 2001 on the HEC
     LADARVision(R) System will be * per Procedure. Commencing on July 1, 2002
     and continuing thereafter during the Term, the Procedure fee for the HEC
     LADARVision System(R) will be determined per Sections 6-8, above. Moreover,
     any SKBM that may have already been procured for this System will be
     eligible for the * contained in this Agreement.

14.    *  LADARVision(R) Systems. Commencing on the Effective Date and
     continuing through June 30, 2002, NovaMed may obtain  *       to be
     installed at locations determined by NovaMed, plus  *               .
     The pricing for these * LADARVision(R) Systems will be * per Procedure for
     all Procedures performed through June 30, 2002. Commencing on July 1, 2002
     and continuing thereafter during the Term, the Procedure fee for these *
     Systems will be determined per Sections 6-8, above.

15.  *

16.  Health Capital Lease Agreements. Certain NovaMed facilities obtained their
     APEX/Infinity lasers through Lease Agreements entered with Health Capital
     Financial Group, L.L.C. (or its assignee) ("Lessor"). Attached hereto and
     incorporated herein as Exhibit B is a list of all the Lease Agreements
     entered between each NovaMed facility and Lessor and the amount owed by the
     facility as of March 1, 2001. All other APEX/Infinity lasers covered by the
     Original Agreement are not subject to any third party financing.

     Upon execution of this Agreement, ALI agrees to  *

*Confidentiality portions omitted and filed separately with the Commission.
<PAGE>

Mr. Stephen Winjum                                        CONFIDENTIAL TREATMENT
February 28, 2001                                         ----------------------
Page 8

     In the event this Agreement is terminated by ALI pursuant to Section 21
     hereof as a result of a default by NovaMed, then NovaMed agrees to
     *                              .

17.  Goods and Services Provided. During the Term, ALI will provide NovaMed with
     use of the Systems, and, at * all necessary maintenance, services, parts,
     gases and optics for the System (defined as the ALI LADARVision(R) System),
     and hardware and software to upgrade the System to the current version of
     the LADARVision(R) 4000 (with such * LADARVision(R) 4000 upgrades to
     include the items identified in Exhibit E, attached hereto and incorporated
     herein, and any other LADARVision(R) 4000 hardware or software upgrades
     that are provided to ALI's other customers * . All SKBMs will have a one-
     year warranty which includes parts and labor. Following the one-year SKBM
     warranty period, ALI will bill and NovaMed agrees to pay for SKBM services
     and parts beyond the Standard Configuration. NovaMed further acknowledges
     and agrees that this Agreement does not include CustomCornea(R) equipment,
     hardware, software or related procedure fees, which may be additional.
     CustomCornea(R) pricing will be determined if, as and when the
     CustomCornea(R) is approved by the FDA; provided, however, that *    . In
     addition, AZI and RH agree that the *. For purposes of this section, *

     As part of the installation of a System, ALI will provide training at no-
     charge for staff members assisting with the operation of the System.

18.  Licensing and Other Documentation. For each System, NovaMed will enter into
     and execute a LADARVision(R) Placement Contract substantially in the form
     of Exhibit C, and a Laser Patent and Software License substantially in the
     form of Exhibit D, and such other documentation not inconsistent with the
     terms of this Agreement as ALI or RH may reasonably request.

19.  Limitation of Liability. Subject to Section 13 of Exhibit C, ALI's and RH's
     liability hereunder is expressly limited to repair or replacement of the
     Systems and/or SKBM's, at ALI's election. In no event will ALI or RH be
     liable for lost profit, injury to goodwill or any other special, incidental
     or consequential damages.

20.  Confidentiality. The parties agree that the terms of this Agreement are and
     shall remain confidential; provided that either party hereto may disclose
     the existence and/or the terms of this Agreement based upon the advice of
     outside counsel that such disclosure must be made in order that such party
     not commit a violation of law or rule of any exchange or stock market on
     which such party's securities are traded and, prior to such disclosure, it
     promptly advises and consults with such other party and its legal counsel
     concerning the information proposed to be disclosed. Notwithstanding the
     foregoing, in no event will either party's disclosure include the amounts
     of the * . In addition, either party may issue a press release announcing
     the existence of this Agreement provided that such party first obtains the
     written approval of the other party with respect to the content and timing
     of such press release, which approval shall not be unreasonably withheld.

*Confidentiality portions omitted and filed separately with the Commission.
<PAGE>

Mr. Stephen Winjum                                        CONFIDENTIAL TREATMENT
February 28, 2001                                         ----------------------
Page 9

21.  Default and Termination.

     a.  In the event NovaMed commits a breach of any of its material
         obligations under this Agreement, and shall fail to cure or diligently
         pursue the cure of such breach within thirty (30) days after NovaMed
         receives written notice from ALI specifying the nature of such breach
         in reasonable detail, then ALI and RH, in their sole discretion, may
         elect one of the following remedies: (i) increase the per Procedure
         fees to * for each Procedure performed on a System, subject to the
         minimum Procedures described in Section 7, and increase the Omnicard
         fee to * per card for all APEX/Infinity lasers, without paying any *
         otherwise payable pursuant to this Agreement; or (ii) terminate this
         Agreement, as well as all LADARVision(R) Placement Contracts and Laser
         Patent and Software Licenses executed pursuant to the terms hereof,
         and, in the event of any such termination, NovaMed shall promptly
         return to ALI all Systems and SKBM's; provided, that NovaMed shall only
         be responsible for paying per Procedure fees for Procedures performed
         on the Systems prior to NovaMed's return of the Systems. ALI's remedies
         herein are cumulative in nature, not exclusive, and the exercise of any
         particular remedy shall not be construed to be an election of remedies
         by ALI nor shall a waiver or delay by ALI of any of its rights or
         remedies under this Agreement be construed as a waiver of ALI's rights
         to enforce any remedies hereunder in the future; provided, however,
         that if ALI elects the remedy set forth in clause (a)(i) above, then
         ALI shall not be able to subsequently elect the remedy set forth in
         clause (a)(ii) for the same breach of the material obligation unless
         ALI (A) provided NovaMed with written notice of its election of the
         remedy in (a)(i), and (B) NovaMed did not cure the breach of the
         material obligation within fifteen (15) days following the receipt of
         such notice. In the event ALI elects the remedy described in clause
         (a)(i), above, upon NovaMed remedying its breach, and provided ALI has
         not terminated this Agreement, then NovaMed shall have the right to
         once again participate * in this Agreement under the original terms and
         conditions of this Agreement.

     b.  In the event (i) the FDA withdraws or materially restricts its approval
         of the APEX/Infinity Laser and/or the System for use in the manner
         currently permitted as of the date of this Agreement, or (ii) there is
         a change to the Patents (as defined in Exhibit D) or NovaMed's use of
         the Systems in accordance with this Agreement is determined by a court
         of competent jurisdiction in an order from which no further appeal can
         be taken to infringe on other patents, and such change or final finding
         of infringement renders the Systems unusable by NovaMed or the NovaMed
         Parties, then NovaMed will have the right to terminate immediately,
         without penalty and any further cost to NovaMed, this Agreement and the
         LADARVision(R) Placement Contracts and Laser Patent and Software
         Licenses. In any event, NovaMed will pay to ALI all money owed as of
         the date of termination.

22.  Assignments. Neither party shall assign or grant any rights or privileges
     under this Agreement or any agreements referred to herein without obtaining
     the prior written

*Confidentiality portions omitted and filed separately with the Commission.
<PAGE>

Mr. Stephen Winjum                                        CONFIDENTIAL TREATMENT
February 28, 2001                                         ----------------------
Page 10

     consent of the other party, which consent will not be unreasonably
     withheld. Any attempted assignment or grant in derogation of the foregoing
     shall be void.

23.  Notice. Notice to ALI and RH shall be sent to Alcon's Legal Department at
     6201 South Freeway, Fort Worth, Texas 76134. Notice to NovaMed shall be
     sent to Stephen Winjum at the address first written above.

24.  Governing Law. This Agreement shall be construed, and the legal relations
     between the parties hereto shall be determined, in accordance with the law
     of the State of Texas, United States of America.

25.  Controlling Agreement. This Agreement constitutes the parties' sole
     agreement and supersedes any prior understandings or written or oral
     agreements between the parties with respect to the subject matter. The
     parties acknowledge and agree that the exhibits will be executed from time
     to time after the date this Agreement is signed, and will be executed by
     NovaMed on the condition that they are subject to the terms and conditions
     of this Agreement. In the event of a conflict between this Agreement and
     any of the exhibits attached hereto, the terms and conditions of this
     Agreement shall control.

26.  Miscellaneous. This Agreement shall not be binding upon the parties and
     shall not obligate any of the parties hereto until it has been signed
     hereinbelow by all parties, in which event it shall be effective as of the
     effective date referenced above. No amendment or modification hereof shall
     be valid or binding upon the parties unless made in writing and signed by
     all parties hereto. If any Section of this Agreement is found by competent
     authority to be invalid, illegal or unenforceable in any respect for any
     reason, the validity, legality or enforceability of such Section in every
     other respect and the remainder of this Agreement shall continue in effect
     so long as the Agreement still expresses the intent of the parties.

If you are in agreement with the foregoing, kindly countersign this letter where
indicated below, whereupon it shall constitute our binding agreement.

*Confidentiality portions omitted and filed separately with the Commission.
<PAGE>

Mr. Stephen Winjum                                       CONFIDENTIAL TREATMENT
February 28, 2001                                        ----------------------
Page 11

Very truly yours,

ALCON LABORATORIES, INC.

By: /s/ BILL BARTON
   ------------------------------

Its:  VPGM
    -----------------------------

REFRACTIVEHORIZONS, L.P.

By: /s/ JEFFREY L. ROPER
   ------------------------------

Its:  Director, Financial Support
    ------------------------------

UNDERSTOOD AND AGREED:

NOVAMED EYECARE SERVICES, LLC

By: STEPHEN J. WINJUM
   ------------------------------

Its:  President & CEO
    ------------------------------

Dated: 2/28/01
      ------------------------------

*Confidentiality portions omitted and filed separately with the Commission.
<PAGE>

                                                          CONFIDENTIAL TREATMENT
                                                          ----------------------

<TABLE>
<CAPTION>
                                                             EXHIBIT B
                                                                 *

                                                                        Lease          Lease                             Remaining
                                      HCFG      Monthly    Serial    Commencement    Expiration              Months        Lease
Lessee                               Lease #     Rent      Number        Date           Date       BANK     Remaining    Obligation
------                               -------    -------    ------    ------------    ----------    -----    ---------    ----------
<S>                                  <C>        <C>        <C>       <C>             <C>           <C>      <C>          <C>
NovaMed Eyecare Mgmt.                 H239         *        5157       11/16/98          *         Fleet        *             *
NovaMed of Richmond                   H240         *        5123        1/22/99          *         Fleet        *             *
NovaMed Eyecare Mgmt.                 H296         *        5198        7/10/99          *         Fleet        *             *
NovaMed Eye Surgery Center            H315         *        5201        7/12/99          *         Fleet        *             *
NovaMed Eye Surgery of New Albany     H332         *        7138        8/21/99          *         Fleet        *             *
NovaMed Eyecare Services, LLC         H352         *        7147         9/1/99          *         Fleet        *             *
NovaMed Eye Surgery of N. Cty.        H354         *        7141        9/16/99          *         Fleet        *             *
NovaMed Management of K.C             H355         *        7146        9/17/99          *          DVI         *             *
NovaMed Surgery of North County, LLC  H353         *        7145        9/15/99          *          DVI         *             *
NovaMed Eye Surgery of Overland Park  H241         *        7122        1/12/98          *          DVI         *             *
Total                                              *                                                                          *
</TABLE>
  *Confidential treatment requested.

*Confidentiality portions omitted and filed separately with the Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}]]